A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Clinical trial NCT04138927 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT04138927
- Sponsor
- Rigel Pharmaceuticals
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-30
- Primary completion
- 2024-04-01
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.